Literature DB >> 20684319

[Differential expressions of the receptor for advanced glycation end products in prostate cancer and normal prostate].

Bin Lu1, Xian-lu Song, Li-yong Jia, Fang-li Song, Shan-chao Zhao, Yong Jiang.   

Abstract

OBJECTIVE: To study the differential expressions of the receptor for advanced glycation end products (RAGE) in the tissues of prostate cancer and normal prostate, and to find the role of RAGE in the pathogenesis of prostate cancer.
METHODS: We collected the tissue of prostate cancer and that of normal prostate from the same patient, and compared the differential expressions of RAGE at the tissue, protein and mRNA levels between prostate cancer and normal prostate tissues of 10 patients by immunohistochemistry, Western blot and real-time quantitative PCR.
RESULTS: Immunohistochemistry exhibited a significantly higher expression of RAGE in the prostate cancer tissue than in the normal prostate tissue; Western blot showed that the RAGE protein expression was 2.13 times higher in the former than in the latter (P < 0.05); and real-time quantitative PCR revealed the RAGE mRNA expression of the former to be 4.2 times that of the latter (P < 0.05).
CONCLUSION: RAGE may play an important role in the pathogenesis and progression of prostate cancer.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20684319

Source DB:  PubMed          Journal:  Zhonghua Nan Ke Xue        ISSN: 1009-3591


  3 in total

1.  AGE/RAGE/Akt pathway contributes to prostate cancer cell proliferation by promoting Rb phosphorylation and degradation.

Authors:  Ji-Ming Bao; Min-Yi He; Ya-Wei Liu; Yong-Jie Lu; Ying-Qia Hong; Hai-Hua Luo; Zhong-Lu Ren; Shan-Chao Zhao; Yong Jiang
Journal:  Am J Cancer Res       Date:  2015-04-15       Impact factor: 6.166

2.  Co-expression of RAGE and HMGB1 is associated with cancer progression and poor patient outcome of prostate cancer.

Authors:  Chu-Biao Zhao; Ji-Ming Bao; Yong-Jie Lu; Tong Zhao; Xin-Hua Zhou; Da-Yong Zheng; Shan-Chao Zhao
Journal:  Am J Cancer Res       Date:  2014-07-16       Impact factor: 6.166

Review 3.  The Taming of Nuclear Factor Erythroid-2-Related Factor-2 (Nrf2) Deglycation by Fructosamine-3-Kinase (FN3K)-Inhibitors-A Novel Strategy to Combat Cancers.

Authors:  Narasimha M Beeraka; Venugopal R Bovilla; Shalini H Doreswamy; Sujatha Puttalingaiah; Asha Srinivasan; SubbaRao V Madhunapantula
Journal:  Cancers (Basel)       Date:  2021-01-14       Impact factor: 6.639

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.